Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 3.02B +106.7% |
| Revenue (ttm) | 865,000 -88.6% |
| Net Income | -283.65M |
| EPS | -4.27 |
| Shares Out | 78.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 743,221 |
| Open | 37.26 |
| Previous Close | 37.51 |
| Day's Range | 37.23 - 38.59 |
| 52-Week Range | 19.72 - 40.30 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 57.07 (+48.29%) |
| Earnings Date | Aug 3, 2026 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,... [Read more]
Financial Performance
In 2025, Celldex Therapeutics's revenue was $1.55 million, a decrease of -77.99% compared to the previous year's $7.02 million. Losses were -$258.76 million, 63.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price target is $57.07, which is an increase of 48.29% from the latest price.
News
Celldex price target raised to $72 from $48 at Wells Fargo
Wells Fargo raised the firm’s price target on Celldex (CLDX) to $72 from $48 and keeps an Overweight rating on the shares. While the Street is modeling a high probability…
Celldex price target lowered to $61 from $67 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Celldex (CLDX) to $61 from $67 and keeps an Overweight rating on the shares. Celldex’s Phase 2 barzolvolimab trial in prurigo nodularis…
Celldex price target lowered to $48 from $54 at Wells Fargo
Wells Fargo lowered the firm’s price target on Celldex (CLDX) to $48 from $54 and keeps an Overweight rating on the shares. While the firm removes PN from its model,…
Celldex price target lowered to $40 from $44 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Celldex (CLDX) to $40 from $44 and keeps an Overweight rating on the shares after the Phase 2 study of barzolvolimab in…
Celldex price target lowered to $60 from $62 at Canaccord
Canaccord lowered the firm’s price target on Celldex (CLDX) to $60 from $62 and keeps a Buy rating on the shares. The firm updated its model after the company reported…
Celldex price target lowered to $70 from $78 at Leerink
Leerink lowered the firm’s price target on Celldex (CLDX) to $70 from $78 and keeps an Outperform rating on the shares.
Celldex to stop skin disease study after trial setback
Celldex Therapeutics said on Tuesday it would discontinue the development of its experimental drug for a skin disease after it failed to meet the main goal and key secondary goals in a mid-stage stu...
Celldex Therapeutics Transcript: Study result
Barzolvolimab failed to meet efficacy endpoints in phase II PN, despite strong mast cell depletion and a favorable safety profile. The study is discontinued, with future focus on urticaria and other indications where mast cells play a clearer pathogenic role.
Celldex Therapeutics Press release: Study result
Celldex Therapeutics issued a press release on July 21, 2026, disclosing material business information to investors.
Celldex Therapeutics Slides: Study result
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Celldex reports barzolvolimab study did not meet primary, secondary endpoints
Celldex (CLDX) reported topline results from the company’s Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis, a chronic skin disease that causes hard, intensely itchy lumps/...
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (P...
Celldex price target raised to $100 from $90 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Celldex (CLDX) to $100 from $90 and keeps a Buy rating on the shares. Ahead of the pivotal EMBARQ-CSU1/2 topline…
Celldex CFO Sam Martin to retire in 2027
Celldex (CLDX) announced that Sam Martin, senior VP and CFO, has informed the company of his plans to retire in 2027. Martin has served as the company’s CFO since 2017…
Celldex Announces Planned Transition of Chief Financial Officer
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to reti...
Celldex Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and approved all four proposals, including director elections, auditor ratification, equity plan amendment, and executive compensation. Strategic updates highlighted strong cash reserves, pipeline progress, and upcoming clinical milestones.
Celldex presents long-term results from Phase 2 study of barzolvolimab
Celldex (CLDX) announced the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology, EAACI,…
Celldex presents first-in-human results for CDX-622
Celldex (CLDX) presented positive results from the Phase 1 healthy participant study of CDX-622 at the European Academy of Allergy and Clinical Immunology, EAACI, Annual Meeting in Istanbul, Turkiye. ...
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the Euro...
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets...
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) a...
Celldex price target raised to $45 from $38 at UBS
UBS raised the firm’s price target on Celldex (CLDX) to $45 from $38 and keeps a Buy rating on the shares. Barzolvolimab’s CSU Phase 3 set-up is favorable for potential…
Celldex Therapeutics Slides: Corporate presentation
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Celldex price target raised to $54 from $38 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Celldex (CLDX) to $54 from $38 and keeps an Overweight rating on the shares. The firm is getting more…
Celldex price target raised to $38 from $34 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Celldex (CLDX) to $38 from $34 and keeps a Neutral rating on the shares.